Skip to main content
Quest Diagnostics

Prior Cycles of Anti-CD20 Antibodies Affect Antibody Responses After Repeated SARS-CoV-2 mRNA Vaccination

Prior Cycles of Anti-CD20 Antibodies Affect Antibody Responses After Repeated SARS-CoV-2 mRNA Vaccinations

Authors: Asashima H, Kim D, Wang K, Lele N, Buitrago-Pocasangre NC, Lutz R, Cruz I, Raddassi K, Ruff WE, Racke MK, Wilson JE, Givens TS, Grifoni A, Weiskopf D, Sette A, Kleinstein SH, Montgomery RR, Shaw AC, Li F, Fan R, Hafler DA, Tomayko MM, Longbrake EE

Citation: JCI Insight. 2023 Aug 22;8(16):e168102. doi: 10.1172/jci.insight.168102.

Specialties: Infectious Disease, COVID-19

Related content

On-Demand Webinar
Combating COVID-19 – Monoclonal Antibody Therapies to Optimize Patient Care
Publication
Estimated SARS-CoV-2 antibody seroprevalence trends and relationship to reported case prevalence from a repeated, cross-sectional study in the 50 states and the District of Columbia, United States-October 25, 2020-February 26, 2022
Test FAQ
SARS CoV 2 Antibody Testing
Conference Presentation
SARS-CoV-2 IGM Detection in Relation To Reactivity In 4 SARS-Cov-2 IGG Assays

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.